GLP-1 Market
LLY $1138.28 ▲ +2.0% NVO $43.45 ▲ +0.9% PFE $27.72 • 0.0% VKTX $31.53 ▼ -1.4% KLRA $13.75 ▼ -1.4% GPCR $38.44 ▼ -0.6% RHHBY $54.80 ▲ +3.9%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Chronocort®

Company
Neurocrine UK Limited
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 15, 2026

Trial details
  • Completed NCT NCT00519818

    Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia

    Not yet reported, Not yet reported Neurocrine UK Limited 20 participants Est. completion 2009-05 1 site
    Other conditions: Congenital Adrenal Hyperplasia, 21-Hydroxylase Deficiency, Adrenogenital Syndrome
    View official trial listing →
  • Completed NCT NCT00915343

    Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency

    Not yet reported, Not yet reported Shire 64 participants Est. completion 2009-01-28
    Other conditions: Adrenal Insufficiency
    View official trial listing →
  • Completed NCT NCT01735617

    Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH

    Not yet reported Neurocrine UK Limited 16 participants Est. completion 2013-12 1 site Stand-alone
    Other conditions: Endocrine Disease, Adrenal Insufficiency, Congenital Adrenal Hyperplasia
    View official trial listing →
  • Completed NCT NCT02716818

    Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia

    Not yet reported Neurocrine UK Limited 122 participants Est. completion 2018-07-28 1 site
    Other conditions: Congenital Adrenal Hyperplasia
    View official trial listing →
  • Completed NCT NCT03019614

    An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone

    Not yet reported Neurocrine UK Limited 30 participants Est. completion 2010-04
    Other conditions: Congenital Adrenal Hyperplasia, Adrenal Insufficiency
    View official trial listing →
  • Completed NCT NCT03051893

    A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of up to 6 Chronocort Formulations

    Not yet reported Neurocrine UK Limited 28 participants Est. completion 2012-04
    Other conditions: Adrenal Insufficiency, Congenital Adrenal Hyperplasia
    View official trial listing →
  • Completed NCT NCT03062280

    A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH

    Not yet reported Neurocrine UK Limited 91 participants Est. completion 2022-07-13 1 site Stand-alone
    Other conditions: Congenital Adrenal Hyperplasia
    View official trial listing →
  • Completed NCT NCT03343327

    A Study of Chronocort® Versus Cortef ® in Healthy Adult Male Subjects

    Not yet reported Neurocrine UK Limited 25 participants Est. completion 2018-04-20 1 site
    Other conditions: Adrenal Insufficiency
    View official trial listing →
  • Withdrawn NCT NCT03532022

    Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

    Not yet reported Neurocrine UK Limited Est. completion 2021-07-09 1 site Stand-alone
    Other conditions: Congenital Adrenal Hyperplasia
    View official trial listing →
  • Completed NCT NCT05063994

    Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

    Not yet reported Neurocrine UK Limited 55 participants Est. completion 2024-02-02 21 sites
    Other conditions: Congenital Adrenal Hyperplasia
    View official trial listing →
  • Completed NCT NCT05222152

    Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency

    Not yet reported Neurocrine UK Limited 58 participants Est. completion 2023-10-18 8 sites
    Other conditions: Primary Adrenal Insufficiency
    View official trial listing →
  • Completed NCT NCT05299554

    Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia

    Not yet reported Immedica Pharma AB 76 participants Est. completion 2026-01-15 21 sites
    Other conditions: Congenital Adrenal Hyperplasia
    View official trial listing →
  • Not yet recruiting NCT NCT07622030

    Hydrocortisone Modified-release in Adults: Real-world Monitoring of Longitudinal Outcomes in coNgenital Adrenal hYperplasia

    IRCCS San Raffaele 100 participants Est. completion 2031-07-31
    Other conditions: CAH - Congenital Adrenal Hyperplasia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Chronocort®, Hydrocortisone modified release

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.